STOCK TITAN

AMYRIS TO PARTICIPATE AT THE UBS GENOMICS 2.0 AND MEDTECH INNOVATIONS SUMMIT

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Amyris, a synthetic biotechnology leader, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 3:00 PM PT in Dana Point, CA. Chief Science Officer Sunil Chandran will represent the company during a fireside chat. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, which employs AI and robotics to scale innovation. The company provides sustainable ingredients used in over 20,000 products globally, reaching more than 300 million consumers.

Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif., Aug. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform, today announced that management will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 10, 2022, at 3:00 pm PT/ 6:00 pm ET in Dana Point, CA. Speaking on behalf of Amyris will be Sunil Chandran, Chief Science Officer and Head of Research and Development.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the company's website at https://investors.amyris.com/events-and-presentations.

About Amyris

Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ technology platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. For more information, please visit http://www.amyris.com.

Amyris, the Amyris logo, and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the U.S. and/or other countries.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-to-participate-at-the-ubs-genomics-2-0-and-medtech-innovations-summit-301598450.html

SOURCE Amyris, Inc.

FAQ

When will Amyris participate in the UBS Genomics 2.0 and MedTech Innovations Summit?

Amyris will participate on August 10, 2022, at 3:00 PM PT.

Who will represent Amyris at the UBS Genomics Summit?

Chief Science Officer Sunil Chandran will represent Amyris.

What is the focus of Amyris's Lab-to-Market technology?

Lab-to-Market technology focuses on sustainable consumption through biotechnology.

How many products use Amyris's sustainable ingredients?

Amyris's ingredients are used in over 20,000 products.

What is the estimated consumer reach of Amyris's products?

Amyris's products reach more than 300 million consumers worldwide.

Where can I find the webcast of Amyris's presentation?

The webcast will be available on the Investor Relations section of Amyris's website.

Amyris Inc

NASDAQ:AMRS

AMRS Rankings

AMRS Latest News

AMRS Stock Data

Petroleum Refineries
Manufacturing
Link
US
Emeryville